News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Agenus (AGEN) Reports First Quarter 2014 Financial Results


5/8/2014 9:08:23 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

Agenus Inc. (NASDAQ:AGEN), an immuno-oncology company developing a portfolio of checkpoint modulators (CPMs), heat shock protein vaccines and adjuvants, today announced its financial results and business highlights for the first quarter ended March 31, 2014.

“I am very pleased to report that shortly following the announcement of the 4-Antibody AG acquisition, we selected our first checkpoint modulator antibody candidates to advance into investigational new drug-enabling studies and raised funding to advance our programs to important value inflection points,” said Garo H. Armen, PhD, chairman and CEO of Agenus.

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES